Pricing Log in Create free account

Boundless Bio, Inc. (BOLD) vs Xilio Therapeutics, Inc. (XLO)

Boundless Bio, Inc. and Xilio Therapeutics, Inc. are both Biotechnology companies. Boundless Bio, Inc. and Xilio Therapeutics, Inc. are of similar size ($55.9M and $54.8M). Boundless Bio, Inc. has the higher net margin (0.00% vs −34.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, Boundless Bio, Inc. leads on 6 and Xilio Therapeutics, Inc. on 5.

Valuation

Metric BOLD XLO Biotechnology median
P/E n/m n/m 10.60
P/S n/m 2.61 9.40
P/B 0.83 2.32 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 0.51 9.02
Earnings yield (116.73%) (17.27%) (32.88%)
Free cash flow yield (103.14%) (36.59%) (23.13%)

Profitability

Metric BOLD XLO Biotechnology median
Gross margin — 100.00% 68.51%
Operating margin 0.00% (48.94%) 0.00%
Net margin 0.00% (34.06%) 0.00%
Free cash flow margin 0.00% (95.59%) 0.00%
Return on equity (67.86%) (55.03%) (51.96%)
Return on assets (50.56%) (15.16%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BOLD XLO Biotechnology median
Revenue growth (TTM) — 327.25% 6.76%
EPS growth (last fiscal year) 32.47% 72.55% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric BOLD XLO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 9.48 4.25 4.97
Net debt to EBITDA 0.99 3.40 1.01

Dividend

Metric BOLD XLO Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BOLD XLO Biotechnology median
Market cap 54.83m 55.93m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack